Dear stakeholders,

On behalf of everyone at the Daiichi Sankyo (DS) Group, I would like to begin by expressing my sincere gratitude for your continued support and understanding regarding our business.

The Mission of the Daiichi Sankyo group of companies is “to contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals and provision of pharmaceuticals addressing diverse medical needs.” “Contributing to the enrichment of quality of life around the world” is in fact our group’s stated Purpose i.e. the reason for existence in society.
<Our Mission and Vision>

Our company started out with the extraction of adrenaline, the discovery of Orizanin, and the domestic production of Salvarsan. Since then, we have continued to address the unmet medical needs of the times by discovering and delivering innovative drugs for cardiovascular diseases, such as dyslipidemia, hypertension, non-valvular atrial fibrillation and venous thromboembolism, as well as antibacterial agents and other pharmaceutical products to people around the world. In 2020, we launched an anti-HER2 antibody-drug conjugate (ADC) as an indication for 3rd line treatment for HER2-positive breast cancer and after that in gastric cancer. As such, we have started to provide treatment solutions to cancer patients with very high unmet medical needs. In the future, we will continue to deliver much-needed medicines to more patients safely and effectively. 

<History as Pharma Innovator>

[ESG Management and Materiality]
Looking ahead, we believe it is critical to focus even more on meeting Environment, Social and Governance (ESG) goals through the DS Value Creation Process. By practicing such long-term focused ESG management and enhancing both financial and non-financial value, we will also generate sustainable growth and value for our company, our stakeholders and society.

With our mid-to long-term corporate value expectations, as well as those of society and our stakeholders, in mind, we identified 8 key issues that need to be addressed for sustainable growth; we call these “Materiality”. We have organized them into those related to the business and those related to our infrastructure. In addition, we have established key performance indicators (KPIs) for each Materiality – targets that we will work to achieve by 2025 to prove our enhanced non-financial value.
<Materiality>

[2030 Vision]
The Daiichi Sankyo 2030 Vision applicable to all group companies, which we announced along with our 5th Mid-term Business Plan (fiscal years 2021–2025) in April 2021, is set to be carried out with a focus on ESG management. That Vision is to become an “innovative global healthcare company contributing to the sustainable development of society”. To realize this vision as well as our purpose, we aim to address the social issues that we are expected to tackle through our business activities, such as the creation of innovative pharmaceuticals and contributing to Sustainable Development Goals (SDGs). We will keep challenging ourselves to continuously provide innovative solutions based on our strengths: our science and technology.
<2030 Vision>

[New 5-year Business Plan]
Our new 5-year business plan is designed to realize our 2025 Goal of being a “Global Pharma Innovator with Competitive Advantage in Oncology,” and to shift to the growth stage towards achieving our 2030 Vision under ESG management.
We have established four strategic pillars for our new 5-year Business Plan.
1. To maximize 3 ADCs (3 antibody-drug conjugates in the field of cancer)
2. Profit growth for current business and products (other than the field of cancer)
3. To identify and build pillars for further growth
4. To create shared value with the stakeholders
We will support the execution of our four strategic pillars through advancing digital transformation (DX).
<New 5-year Business Plan>


The COVID-19 pandemic is still highly prevalent around the world. In order to fulfill our mission as a pharmaceutical company, we are working to prevent infection among employees and other stakeholders by creating practices and policies within our affiliates globally that put health and wellbeing at the top of our priorities. At the same time, we are continuing to provide a stable supply of pharmaceuticals, and to undertake the research and development of innovative pharmaceuticals. As we engage with our customers, we are striving to reduce the burden on the medical field by promoting efficient and effective communication among healthcare professionals using DX and other technologies.

As a pharmaceutical company with strengths in science and technology and a vaccine business infrastructure in place, we are also developing vaccines and treatments for COVID-19, which are urgently needed in society.
<COVID-19 Initiatives>

I hope that this website will help our stakeholders understand how we are addressing social issues and what value we aim to deliver to society.

 

 

Sunao Manabe  
Representative Director  
Executive Chairperson and CEO